Phase II trial code: 1066

Registry ID

ISRCTN35638452

Source registry

ISRCTN

Status

Recruiting

Phase

PHASE2

Study type

INTERVENTIONAL

Sponsor

University of Leicester

Enrollment

96

Start date

2025-08-31

Completion date

2027-12-31

Last update

2026-08-17

Conditions

• Respiratory

Summary

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Detailed description

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Interventions

• DRUG: The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Inclusion criteria

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Exclusion criteria

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Locations

• , , Spain
• , , Netherlands
• , , Denmark
• , , United Kingdom

Related clinical trials

• Exacerbation Prevention in chronic obstructive pulmonary disease (COPD) - using High Flow Therapy at home to reduce hospital readmission (EPIC-HFT UK)
• CLArithromycin for post-Stroke Pneumonia
• The study aims to investigate the effect of the level of probiotic K12 content on enhancing children's immunity and reducing the frequency of their occurrence of diseases such as pharyngitis, tonsillitis, and rhinitis
• A study to compare a single drainage procedure (therapeutic aspiration) versus a standard chest tube for the initial treatment of infected fluid around the lung
• Effects of blocking a messaging protein called TSLP (thymic stromal lymphopoietin) on inflammation in the airways
• Asthma care for children and adolescents in Uganda

View on source registry